Drug Trial Radar · NCT06159478
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jun 30, 2023
Primary completion
Feb 28, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- National Cancer Center, JapanGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Dec 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.
Conditions
- Low-grade Glioma
- Pancreatic Cancer
Interventions
Binimetinib 15 MGDrug
Binimetinib 45mg is orally administered twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (centrally assessed)Time frame: Baseline up to 4 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Kyushu University Hospital
Fukuoka, Fukuoka, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Kyoto University Hospital
Kyoto, Kyoto, Japan · Recruiting
Tohoku university Hospital
Sendai, Miyagi, Japan · Recruiting
National Cancer Center Japan
Chuo-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.